Macquarie Group
BHVN

Macquarie Group’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

Macquarie Group’s Portfolio BHVN Stock Details BHVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-62,875
Closed -$9.16M – 2585
2022
Q2 		$9.16M Sell
62,875
-690,008
-92% -$88.1M 0.01% 887
2022
Q1 		$89.3K Buy
752,883
+14,684
+2% +$1.83M 0.07% 328
2021
Q4 		$102M Buy
738,199
+218,075
+42% +$27.7M 0.08% 300
2021
Q3 		$72.3M Buy
520,124
+518,251
+27,670% +$64.7M 0.06% 413
2021
Q2 		$182K Sell
1,873
-72
-4% -$5.84K ﹤0.01% 1822
2021
Q1 		$133K Sell
1,945
-453
-19% -$36.6K ﹤0.01% 1824
2020
Q4 		$206K Hold
2,398
– – ﹤0.01% 1654
2020
Q3 		$156K Hold
2,398
– – ﹤0.01% 1675
2020
Q2 		$175K Buy
2,398
+1,298
+118% +$69.1K ﹤0.01% 1589
2020
Q1 		$37K Hold
1,100
– – ﹤0.01% 1848
2019
Q4 		$60K Buy
+1,100
New +$54.5K ﹤0.01% 1840

Other funds holding BHVN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
Stifel Financial
Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
SFM
Soros Fund Management New York $9.12B AUM 30.69% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Macquarie Group's BHVN Position: Q3 2022 in Review

Macquarie Group sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q3 2022, closing a stake of 62,875 shares — an estimated $9.16M sold.

Macquarie Group first reported a position in BHVN in Q4 2019 and held it in 11 quarters. The position peaked at $102M in Q4 2021. 240 funds tracked by Wall St. Rank hold BHVN as of Q3 2022.

  • Macquarie Group reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q3 2022 after selling out during the quarter.
  • Macquarie Group sold 62,875 Biohaven Pharmaceutical Holding Company Ltd. shares in Q3 2022, an estimated $9.16M.
  • Macquarie Group first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q4 2019 and held it in 11 quarters.
  • Macquarie Group's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $102M in Q4 2021.
  • 240 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q3 2022.

Based on Macquarie Group's 13F filing for Q3 2022, filed 14 Nov 2022.